The aim of this study was to evaluate the synergistic antiangiogenic effect of low dose of vinblastine (VBL) and rapamycin (RAP) in neuroblastoma (NB). Both in vitro (endothelial cells proliferation assay; TUNEL assay; phosphatidylserine exposure and cell cycle analysis) and in vivo (chick embryo chorioallantoic membrane, CAM) assays were used. Each compound alone was able to induce a significant dose-and time-response inhibition of in vitro endothelial cells (EC) growth. Interaction index evaluation indicates that a synergistic effect was found when both drugs were combined at very low doses. Comparable effects were obtained when EC were preincubated with conditioned medium (CM) derived from the human NB cell line HTLA-230. Morphological changes were induced by each drug, and their combination resulted in a clear and stronger effect. Apoptosis was demonstrated by the TUNEL assay and confirmed by Annexin V-FITC staining of EC treated with VBL, showing an increase in the percentage of cells with a G2-M and sub-G1 DNA content, whereas in those treated with RAP a block in the G1 cell fraction and inhibition of progression to the S phase were observed. Here too, the combination resulted in a synergistic cell cycle arrest and induction of apoptosis. Similar results were obtained in vivo with the CAM assay. The angiogenic responses induced by HTLA-230-derived CM, NB tumor xenografts, and human NB biopsy specimens were inhibited by each drug and more significantly by their combination. The observation that these well-known drugs display synergistic effects as antiangiogenics when administered frequently at very low dose may be of significance in the designing of new ways of treating NB. Oncogene (2005) 24, 6785-6795.
Introduction
Angiogenesis occurs in both physiological and pathological conditions, and in solid tumor growth a specific clinical turning point is the transition from the avascular to the vascular phase (Hanahan and Folkman, 1996) . A soluble tumor angiogenesis factor (TAF), observed in tissue extracts from several tumors, including human neuroblastoma (NB), has been identified Phillips et al., 1976) . Over the last 10 years several reports have examined the in vitro and in vivo relationship between tumor progression and angiogenesis in NB, and a high vascular index in NB correlates with poor prognosis (reviewed in Ribatti et al., 2002) . This suggests that aggressive tumor growth depends on active angiogenesis, because once it develops an intrinsic vascular network, it grows indefinitely both in situ and at distant sites (metastasis), since its cells enter the vascular bed and colonize other organs (Fidler and Ellis, 1994) .
Antiangiogenesis management should be effective against many tumors, and the development of drugs to inhibit angiogenesis has become an attractive approach to cancer therapy (Folkman, 1971) . Angiostatic treatment of NB has also been proposed and several angiostatic agents have been tested: the synthetic analogue of fumagillin, TNP-470 (Nagabuchi et al., 1997; Wassberg et al., 1997a, b) , the endogenous steroid 2-methoxyestradiol and its derivative 2-propylestradiol (Wassberg et al., 1997a, b) , and thalidomide (Kaicker et al., 2003) .
Conventional treatments, that is, surgery, chemo-and radiotherapy, have considerably improved the outcome of NB in childrens. However, NB with unfavorable properties often fails to respond persistently to these treatments and is eventually fatal (Maris and Matthay, 1999) .
Standard chemotherapy regimens for many pediatric solid tumors require courses of intensive agents given in combination every 3-4 weeks to allow recovery of marrow functions prior to each new course. Long-term, regular low-dose administration of such agents ('metronomic', i.e. very frequent or continuous low-dose chemotherapy) could inhibit endothelial cell (EC) proliferation, angiogenesis, and tumor growth , and by attacking the vasculature, chemotherapy-induced drug resistance may be circumvented, because EC are considered to be genetically more stable than tumor cells Kerbel, 2001) . We have previously studied the antiangiogenic activities of vinblastine (VBL) on in vitro and in vivo angiogenesis assays (Vacca et al., 1999) . Moreover, VBL has been previously experimentally used in NB . Guba et al. (2002) showed that the macrocyclic antibiotic rapamycin (RAP), a mTOR inhibitor with immune-suppressant activities, inhibits tumor growth and angiogenesis in mouse models through a decrease in the production of vascular endothelial growth factor (VEGF) and a markedly inhibited EC response to stimulation with VEGF. Moreover, Misawa et al. (2003) have demonstrated that RAP inhibits in vitro proliferation of human NB cells. VBL and RAP exert their antiangiogenic activity with different mechanisms. In fact, while VBL at very low doses strikingly and reversibly impacts certain functions of EC and angiogenesis without nonspecific cytotoxic or necrotic damage (Vacca et al., 1999) , RAP directly inhibits tumor cell proliferation by cell cycle arrest and targeted reduction of VEGF (Guba et al., 2002) .
This study presents new information derived from in vitro and in vivo assays to illustrate the antiangiogenic activity of VBL and RAP, singly and in combination.
Results

Effects of VBL and RAP on EC proliferation
To study the antiproliferative effects of low doses of VBL and RAP, EA.hy926 and HUVEC cells were plated at low-density cultures and treated with different drug concentrations. Figure 1a and b show doseresponse curves, demonstrating that each compound alone significantly inhibited EA.hy926 cells proliferation. VBL was already effective at 1.25 pM and resulted in a complete inhibition of cell growth near to 250 pM; RAP started to be effective at around 3 pM; however, it did not induce complete inhibition of EC proliferation up to 1000 pM. Synergy is defined as a combination of two drugs that has a greater therapeutic effect than what would be expected by the simple addition of the effects of each drug. To determine whether our drug scheduling exhibited increased synergistic antiproliferative activity, different combinations of concentrations of VBL and RAP were added to EC. From the dose-response curves, the concentration at which EA.hy926 cells proliferation was inhibited to 80% of control was calculated. Figure 1c shows the isobologram generated A measure of the synergism was further obtained from the value of g, a quantity that indicates the changed potency of the combination. Table 1 shows g values at IC 80 for EA.hy926 cells treated with different combinations of VBL and RAP and clearly underlines that a synergistic effect is found when these two compounds are combined at low doses.
When EA.hy926 cells were pretreated with HTLA-230 CM, their proliferative rate was greatly increased (Figure 1d ). Inhibition of proliferation was already apparent after 1.25 pM VBL and 10 pM RAP monotherapy. To rule out the possibility of specimen heterogeneity, the t-test with Welch's correction was applied to calculate the significance of the different effects, indicating that a significative increment was evident when the two drugs were added in combination.
Similar results were obtained by using HUVEC cells (data not shown).
Morphological changes induced in EC by VBL and RAP
The morphological changes induced by VBL and RAP were determined by treating EA.hy926 cells for 48 h with control medium, 50 pM VBL, and 0.5 nM RAP alone or in combination. In these mechanism-oriented experiments we deliberately used an earlier time and slightly higher doses than those of Figure 1 to avoid having to work on terminal induced, almost dead, cells. Phase contrast microscopy revealed characteristic morphologic alterations in all the treated cells (Figure 2 , panels a-d). Cells cultured with VBL (panel b) were rounded, more refractive, denser, and partially detached, suggesting induction of apoptosis. Those treated with RAP (panel c) became sparse and extremely elongated. These two morphological aspects were more clearly visible on a few altered EC when the combination was used (panel d).
Effects of VBL and RAP on apoptosis in EC
To establish whether EC response to VBL and RAP induced apoptosis, EA.hy926 cells were treated for 48 h with 50 pM VBL and 0.5 nM RAP, alone or in combination. As shown in Figure 2 (panels e-h), the TUNEL assay, which measures DNA strand breaks in individual cells, revealed no apoptosis in negative controls (panel e) and only few apoptotic cells following treatment with RAP (panel g), whereas some bright green fluorescent and adherent EC were recognizable after treatment with VBL (panel f), together with a dramatic enhancement of cell detachment (cytospin, inset panel f). The combination resulted in a higher percentage of apoptotic cells and apoptotic bodies, particularly among the detached cells (panel h and inset). Similar results were obtained with HUVEC (data not shown).
Better quantification of the early and late apoptosis percentage was achieved by exposing EA.hy926 to the same drug concentrations for various times, followed by flow cytometry after double annexin V-FITC conjugate and PI staining. As shown in Figure 3 , after 4 h apoptosis was only detected in cells treated with the combination, whereas no apoptotic effect was induced at this time by each drug on its own. After 24 and 48 h, however, apoptosis was also observed in cells treated with VBL. The synergistic apoptotic effect of the combination was nonetheless time dependent.
Inhibition of EC cycle progression by VBL and RAP
To determine whether induction of the synergistic antiproliferative and apoptotic effects of the combination was coupled with inhibition of cell cycle progression, EC were incubated for 48 h in the presence of complete medium, 50 pM VBL, 0.5 nM RAP or 50 pM VBL plus 0.5 nM RAP and pulsed-labeled with BrdU. BrdU uptake vs total cellular DNA content was then evaluated by densitometric FACS analysis ( Figure 4 ). VBL (panel b) induced an increase in the percentage of cells with a G2-M (R5 quadrant) and sub-G1 (R2) DNA content, suggesting a G2-M block of the cell cycle before entering the apoptotic program, whereas RAP (panel c) induced a block in the G1 cell fraction (R3) and inhibition of progression to the S phase (R4). VBL plus RAP caused a dramatic decrease in the S phase and a sustained block of the G2-M phase, suggesting that this mechanism underlies their synergistic antiproliferative and apoptotic effects.
In vivo chorioallantoic membrane (CAM) assay
Macroscopic examination was performed on day 12 of incubation. CAM treated with sponges loaded with FGF-2 (positive control) and those loaded with the CM of the HTLA-230 line showed numerous allantoic vessels radiating in a 'spoked wheel' pattern towards the sponges and the grafts ( Similar results were obtained when the CAM were treated with NB biopsy specimens and xenografts. Tumor specimens grafted onto CAM were surrounded after 96 h by numerous allantoic vessels that invaded the implants ( Figure 5 , panels e and f), whereas these vessels were significanly fewer in specimens treated with the drug combination ( Figure 5 , panels i and l). Once again, morphometric confirmation was provided by the significantly enhanced angiostatic activity obtained by treating the NB xenografts (Figure 6b ) or the biopsy specimens (Figure 6c ) with the combination (Po0.01 vs xenograft or biopsy specimen alone) compared with treament with the single drugs (Po0.05).
Discussion
This is the first in vitro and in vivo demonstration that the antiangiogenic effect of a combination of VBL and RAP at very low doses against human NB is greater than the sum of the effects of the two drugs administered alone. These experimental data agree with the general Tumor angiogenesis does not depend on a single molecule, since many angiogenic inducers and inhibitors are simultaneously expressed. A systematic analysis of angiogenic factors in 22 human NB cell lines and in 37 human NB tumor samples by Eggert et al. (2000) showed that high expression levels of seven angiogenic factors correlated strongly with the advanced stage of NB, suggesting that several angiogenic peptides act in concert to regulate neovascularization. This indicates that therapy targeting a single angiogenic factor is unlikeky to be effective. For example, blockade of the VEGF pathway seems too narrow as an approach to inhibit angiogenesis beacuse a tumor may use a compensatory pathway. It has been suggested that combination of two or more angiogenesis inhibitors may be more effective than single-drug treatment. Combination of inhibitors with different mechanisms of action attacking different biochemical pathways should shut down the multifactor stimulated cascade of biochemical angiogenic processes. In addition to VEGF, NB cells express platelet-derived growth factor (PDGF) and stem cell factor (SCF) along with their receptors, PDGFR and c-Kit. Beppu et al. (2004) evaluated the effects of imatinib mesylate (Imatinib), a selective inhibitor of the tyrosine kinase activity of c-Kit and PDGFR, on the growth of NB. They showed that mice treated with nontoxic doses of Imatinib have significantly smaller tumors than control mice. This inhibition was clearly associated with suppression of PDGFR and c-Kit phosphorylation and inhibition of VEGF expression, suggesting the potential utility of VEGF-targeted treatments in association with other antitumor strategies in NB management.
It is unclear which agent combinations would be most efficacious and have the highest degree of synergistic activity. The combination of angiogenesis inhibitors with low-dose antiangiogenic chemotherapy constitutes an interesting approach. Enhanced antiangiogenic effectiveness has been reported for the combination of endostatin with angiostatin (Yokoyama et al., 2000) , with chemotherapeutic agents (Te Velde et al., 2002) , and with a VEGF-receptor-2 (VEGFR-2) receptor tyrosine kinase inhibitor (Abdollahi et al., 2003) . In contrast, the dual blockade of VEGFR and epidermal growth factor receptor (EGFR) by small molecules that block receptor tyrosine kinases of the same family did not result in enhanced antitumor activity (Baker et al., 2002) . Bergers et al. (2003) reported that the combination of the tyrosine kinase inhibitors SU5416 (selective for VEGFR-1 and -2) and SU6688 (selective for platelet derived growth factor receptor (PDGFR)) was more efficacious against the progression of a murine islet cell carcinoma than either alone agent.
Antiangiogenic combinations have also been employed in NB. Klement et al. (2000) subjected two NB cell lines to continuous treatment with low doses of VBL and an anti-VEGFR-2 neutralizing antibody, both singly and in combination. Each single-agent treatment resulted in significant, but transient, xenograft regression and diminished tumor vascularity, whereas the combination led to full and sustained regression of large established tumors. Kim et al. (2002) demonstrated that topotecan, either with or without anti-VEGF antibody, specifically suppresses NB xenograft growth in comparison with controls or the antibody alone. Moreover, combination of topotecan with the antibody significantly inhibited rebound tumor growth in Figure 6 Morphometric evaluations of the angiogenic response in the CAM assay. Gelatin sponges were loaded with the CM of HTLA-230 cells and implanted in the CAM on day 8 of incubation (panel a); CAM were grafted with HTLA-230 xenografts (panel b) or human NB biopsy specimens on day 8 of incubation (panel c). Macroscopic (number of blood vessels converging toward the sponges or the grafts, white bars), microscopic (microvessel density calculated as number of intersection points according to a planimetric method of point counting, hatched bars), and as % area (black bars) assessment of vascular density on day 12 of incubation (*Po0.05; **Po0.01 vs control) with or without VBL (1.25 pM) and RAP (10 pM), alone or in combination Antiangiogenesis by vinblastine and rapamycin D Marimpietri et al comparison with the antibody alone. Svensson et al. (2002) showed that CHS 828 is a potent inihibitor of experimental NB growth in vivo, both alone and in combination with antiangiogenic drugs, such as TNP-470 or SU 5416, at doses not causing systemic toxicity. Its efficacy is increased by both TNP 470 and SU 5416.
Our results indicate that VBL and RAP exerted an in vitro antiproliferative effect on untreated EC and those stimulated with NB-derived CM, and that this effect is enhanced by their combination. Bayless and Davis (2004) have recently demonstrated that VBL and other microtubule-depolymerizing agents collapse both EC tubular networks in vitro and angiogenic blood vessels in vivo, and induce apoptosis after the tube collapse. In our study, the data of Figure 3 and some preliminary results obtained with the TUNEL assay seem to indicate that VBL induced EC apoptosis, particularly that of detached cells and this may be responsible for its inhibition of angiogenesis. Many normal cell types, including epithelial cells and EC, undergo apoptosis on detachment from their substrate (anoikis) (Meredith and Schwartz, 1997) . Understanding anoikis seems to be of particular importance for cancer research, and restoration or induction of anoikis in a tumor's vasculature could thus be regarded as a new way of controlling its growth.
RAP itself did not induce apoptosis, but produced a cytostatic effect that seems to accelerate anoikis. EA.hy926 cells were sensitized to anoikis by VBL plus RAP, as previously reported (Fukazawa et al., 2002) . This combination induced the rapid apoptosis of a higher percentage of cells than each agent alone and displayed a synergistic antiangiogenic effect. Microtubule inhibitors such as VBL induce G2-M cell cycle arrest and subsequently apoptosis in a wide variety of cell lines (Page and Hieter, 1999) , while RAP blocks vascular EC in the G1 phase and inhibits growth factor stimulation of protein synthesis, this being closely correlated with the inhibition of cell proliferation (Vinals et al., 2002) . Here, we show that VBL increased the percentage of EC with a G2-M and sub-G1 DNA content, suggesting a G2-M block before apoptosis, whereas RAP increased the G1 cell fraction, indicating an inhibition of the passage from the G1 to the S phase. The drastic decrease in the percentage of cells in the S phase induced by VBL plus RAP may constitute the mechanism through which the combination exerted its synergistic antiproliferative effect.
Lastly, the combination inhibited the angiogenic response induced when CM derived from NB cells, NB biopsy specimens or NB cell line-derived tumor xenografts were implanted in the CAM.
The possibility that the combination may be responsible for nonangiogenesis-related effects, including the direct reduction of tumor cell growth, cannot be ruled out. Even so, our in vitro and in vivo observations indicate that its antiangiogenic activity rapidly inhibits tumor expansion by depriving tumor cells of oxygen and nutrients and limiting their proliferation. Studies to validate the role of the combination of VBL and RAP are needed to assess the prognostic significance of tumor vasculature.
Materials and methods
Chemotherapeutics VBL (Lilly France SA, Saint Cloud, Paris, France) was solubilized in phosphate-buffered saline (PBS) and diluted stepwise from 250 to 0.625 pM with the culture medium. RAP (ICN Biomedicals Inc., South Chillicothe Road Aurora, OH, USA) was solubilized in DMSO and diluted stepwise from 1 nM to 1.56 pM with the culture medium.
Cell lines and culture conditions
The human NB cell line HTLA-230 (Bogenmann, 1996) and the human endothelial-like immortalized cell line EA.hy926 (Edgell et al., 1983) were maintained in logarithmic growth in 75-cm 2 plastic culture flasks (Corning, Bibby Sterilin, UK) in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FBS (Sigma Chemical Co., St Louis, MO, USA), 50 IU/ml sodium penicillin G, 50 mg/ml streptomycin sulphate, and 2 mM L-glutamine, as previously described (Ponzoni et al., 1995; Vacca et al., 1999) . Human umbilical vein endothelial cells (HUVEC) were prepared and grown as previously described (Ponzoni et al., 1995) .
Preparation of the conditioned medium
Conditioned medium (CM) was prepared from HTLA-230 NB cell line, as previously described (Ribatti et al., 1998) . Briefly, cells were harvested in Tripsin/EDTA solution, washed twice in PBS and placed in a 25 cm 2 culture flask (2 Â 10 6 cells per flask) in complete medium for 2 days. At the end of the incubation, CM was collected, sequentially centrifuged at 3000 and 15 000 g for 10 min, filtered through 0.22-mm pore size filters (Costar, Cambridge, MA, USA), and stored at À801C.
Proliferation assay
EC were plated (2 Â 10 3 /well) in 96-well plates in their complete medium. After 24 h, the medium was removed and replaced on days 1, 3, and 5 in quadruplicate by the same medium (control) or supplemented with VBL (0.625-250 pM) and RAP (1.56-1000 pM), with or without CM. The cell number was estimated on day 6 by the colorimetric assay of Kueng et al. (1989) modified as follows: cells were fixed for 20 min at room temperature with 4% paraformaldehyde (PFA), stained with 0.1% crystal violet in 20% methanol for 20 min, washed in PBS, solubilized with 10% acetate, and read at 595 nm in a microplate reader (SpectraFluor Plus, Tecan, Austria). The cell number was derived from a calibration curve set up with known numbers of cells plated in sextuplicate.
TUNEL assay
EC (4 Â 10 4 /well) were plated in chamber slides and, after 24 h of culture, were treated with VBL (50 pM) and/or RAP (0.5 nM) (Nunc, Naperville, IL, USA); after further 48 h, supernatants were collected and cytocentrifuged onto polylisine-glass slides. DNA cleavage was assessed by enzymatic end-labeling of DNA strand breaks using a commercial kit (In Situ Cell Death Detection Kit) (Roche, Penzberg, Germany), according to the manufacturer's instructions. Briefly, slides (with adherent cells or cytospin preparations) were air dried and fixed in 4% PFA for 1 h at room temperature, washed in PBS, and permeabilized with 0.1% Triton X-100 and 0.1% sodium citrate for 2 min at 41C; after rinsing, slides were incubated with 50 ml of TUNEL reaction mixture, containing terminal deoxynucleotidyl transferase (TdT) and FITC-labeled dUTP, in a humidified atmosphere for 1 h at 371C in the dark. Rinsed slides were then coverslipped with Vectashield mounting medium containing 4 0 ,6 0 -diamidino-2-phenylindole (DAPI) (Vector Laboratories, Burlingame, CA, USA) for nuclear counterstaining. Cells were analysed under a Nikon Eclipse E1000 epifluorescent microscope (Nikon Corporation, Tokyo, Japan) with appropriate DAPI and FITC filter sets. The images were acquired with a high-sensitivity monochrome charge-coupled device (CCD) camera.
Phosphatidylserine exposure
Phosphatidylserine (PS) exposure was assessed with a human Annexin V-FITC Kit (Bender MedSystems, Vienna, Austria). Briefly, cultured and treated cells (see legend of Figure 3) were collected, washed, and incubated for 10 min with 5 ml Annexin V-FITC, washed once with PBS, resuspended in 190 ml prediluted binding buffer containing 10 ml of a 20mg/ml propidium iodide (PI) stock solution, and examined by two color flow cytometry using a FACScan (Beckton Dickinson, San Jose, CA, USA) equipped with a xenon lamp and a filter set for excitation at 488 nm; FITC and PI fluorescence intensities were recorded through 520-530 (FL1-H) and 575 (FL2-H) nm filters, respectively. At least 10 000 events were collected in each dot plot and analysed using Cell Quest software (Beckton Dickinson, San Jose, CA, USA). Cells that stained negative for both Annexin V-FITC and PI staining were viable and did not undergo measurable apoptosis (lower left quadrant); those that stained positive for Annexin V-FITC and negative for PI were in the early stages of apoptosis (lower right quadrant); cells that stained positive for both Annexin V-FITC and PI were either in the later stages of apoptosis (upper right quadrant) or dead (upper left quadrant).
Analysis of DNA synthesis by BrdU pulse-labeling technique
Exponentially growing EC (2 Â 10 6 ) were treated for 48 h with VBL (50 pM) and/or RAP (0.5 nM), pulsed-labeled with 10 mM BrdU (Sigma) 4 h before harvesting, washed twice in 1% BSA/ PBS, and fixed with 70% ice-cold ethanol ON at À201C. They were then incubated for additional 30 min at room temperature with 2N HCl/0.5% triton X-100 to denature the DNA and produce single-stranded molecules, washed in 0.1 M Na 2 B 4 O 7 pH 8.5 to neutralize the acid, and resuspended in 0.5% Tween 20/1% BSA/PBS. BrdU taken up was stained with 20 ml FITCconjugated anti-BrdU mouse monoclonal antibody (Becton Dickinson, Milan, Italy) for 30 min at room temperature. Samples were then washed and resuspended in PBS containing 5 mg/ml PI. Bivariate distributions of BrdU amounts (FITC) vs DNA content (PI) were assessed by flow cytometry. At least 20 000 events were collected in each final densitometric plot.
Patients and collection of tumor samples
In all, 10 NB specimens collected from 1987 to 1998 were retrieved from the Italian Neuroblastoma Tissue Bank at the onset of the Ethical Committee of the G Gaslini Children's Hospital, and all patients or their parents gave informed consent (Table 2) .
NB xenografts in nude mice
Female 4-5-week-old CD1 nu/nu mice were purchased from Harlan Laboratories (Harlan Italy, S Pietro al Natisone, Italy) and housed in sterile enclosures under specific virus and antigen-free conditions. All procedures involving animals and their care were in accordance with institutional guidelines and both national and international laws and policies. Animals were injected intravenously (i.v.) with 3.5 Â 10 6 HTLA-230 cells. After 30-40 days, they developed kidney, adrenal gland, ovary, and liver metastases, as previously described (Bogenmann, 1996; Pastorino et al., 2003) . After 40-50 days, they were killed and metastases were collected and stored at À801C.
CAM assay
Fertilized White Leghorn chicken eggs (10 per group) were incubated at 371C at constant humidity. On day 3, a square window was opened in the shell, and 2-3 ml of albumen was removed to allow detachment of the developing CAM. The window was sealed with a glass, and the eggs were returned to the incubator. On day 8, eggs were treated with the following: (i) 1 mm 3 sterilized gelatin sponges (Gelfoam Upjohn, Kalamazoo, MI, USA) placed on top of the growing CAM, according to Ribatti et al. (1997) and loaded with 1 ml of PBS as negative control, 1 ml of PBS containing 500 ng of recombinant fibroblast growth factor-2 (FGF-2) (R&D Systems, Abington, UK) as positive control; 1 ml of CM from HTLA-230 line alone or admixed to 1.25 pM VBL and 10 pM RAP, alone or in combination; (ii) 1-2 mm 3 biopsy fragments from xenografts derived from HTLA-230 line injected in nude mice and grafted onto the CAM alone or with 1.25 pM VBL and 10 pM RAP, administered alone or in combination; (iii) fresh biopsies from patients with NB collected under sterile fragments and were grafted onto the CAM alone or admixed with 1.25 pM VBL and 10 pM RAP, administered singly or in combination. CAMs were examined daily until day 12 and photographed in ovo with a stereomicroscope equipped with a camera and image analyser system (Olympus Italia, Italy). At day 12 the angiogenic response was evaluated by the image analyser system as the number of vessels converging toward the sponges or the grafts. CAMs were then processed for light microscopy. Briefly, the embryos and their membranes were fixed in ovo in Bouin's fluid. The sponges and grafts and the underlying and immediately adjacent CAM portions were removed and processed for embedding in paraffin. Serial sections (8 mm) were cut in a plane parallel to the surface of the CAM, stained with a 0.5% acqueous solution of toluidine blue (Merck, Darmstadt, Germany) and observed under a Leitz-Dialux 20 light photomicroscope (Leitz, Wetzlar, Germany).
The angiogenic response was assessed by a planimetric method of point counting (Ribatti et al., 1997) . Microvessel density was expressed as percentage of the total number of intersection points occupied by vessels cut transversely (diameter 3-10 mm). Mean values7s.d. were determined for each analysis.
Statistics
To determine whether drug combinations exhibited synergistic antiproliferative activity, isobolographic analysis was performed. From the dose-response curves, the concentration at which EC proliferation was inhibited to 80% of control level was calculated to generate an isobologram. The diagonal line shows the theoretical line indicating additive effects: the points below the line indicate synergistic activity whereas those above represent subadditivity. Different combinations of VBL and RAP were added to endothelial, cells and the values obtained plotted in the isobologram.
The degree of enhanced effect was also measured from the interaction index (g); a quantitative marker for the drug combination and effect metric used. If g ¼ 1, the interaction is additive, if go1, it is superadditive (synergistic), and if g>1, it is subadditive. Isobolar analyses and calculation of g were analysed by the method of Tallarida (Tallarida, 2001 (Tallarida, , 2002 .
All in vitro data are from three or more independent experiments. Results are expressed as means795% confidence intervals (CIs). The significance of differences between experimental groups and controls was determined by the unpaired t-test with Welch's correction (Keselman et al., 2004) and with two-tailed Po0.05 as the cutoff.
